Samjin Pharm
Samjin Pharmaceuticals Co., Ltd. manufactures and sells medicine. It offers medicine in oral, drop, and injecting forms. The company provides over-the-counter medicines, such as Gevorin, an anti-infalammatory pain killer; Trestan, an appetite stimulant; Flaris, an anti-thrombotic agent; and Nutilin, a brain function improvement agent, as well as medicine for treatment of chronic diseases. It also… Read more
Samjin Pharm (005500) - Total Assets
Latest total assets as of September 2025: ₩449.14 Billion KRW
Based on the latest financial reports, Samjin Pharm (005500) holds total assets worth ₩449.14 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Samjin Pharm - Total Assets Trend (2013–2024)
This chart illustrates how Samjin Pharm’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Samjin Pharm - Asset Composition Analysis
Current Asset Composition (December 2024)
Samjin Pharm's total assets of ₩449.14 Billion consist of 37.4% current assets and 62.6% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0.8% |
| Accounts Receivable | ₩62.50 Billion | 14.7% |
| Inventory | ₩91.74 Billion | 21.6% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩21.52 Billion | 5.1% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Samjin Pharm's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Samjin Pharm's current assets represent 37.4% of total assets in 2024, a decrease from 64.4% in 2013.
- Cash Position: Cash and equivalents constituted 0.8% of total assets in 2024, down from 1.3% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 1.0% in 2013.
- Asset Diversification: The largest asset category is inventory at 21.6% of total assets.
Samjin Pharm Competitors by Total Assets
Key competitors of Samjin Pharm based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Samjin Pharm - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Samjin Pharm generates 0.73x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Samjin Pharm generates $9.23 in net profit.
Samjin Pharm - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.25 | 1.05 | 4.15 |
| Quick Ratio | 0.52 | 0.45 | 2.34 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩37.31 Billion | ₩ 6.64 Billion | ₩ 123.14 Billion |
Samjin Pharm - Advanced Valuation Insights
This section examines the relationship between Samjin Pharm's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.84 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 1.3% |
| Total Assets | ₩425.17 Billion |
| Market Capitalization | $73.90 Million USD |
Valuation Analysis
Below Book Valuation: The market values Samjin Pharm's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Samjin Pharm's assets grew by 1.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Samjin Pharm (2013–2024)
The table below shows the annual total assets of Samjin Pharm from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩425.17 Billion | +1.25% |
| 2023-12-31 | ₩419.90 Billion | +3.28% |
| 2022-12-31 | ₩406.56 Billion | +22.27% |
| 2021-12-31 | ₩332.50 Billion | +23.59% |
| 2020-12-31 | ₩269.03 Billion | +10.19% |
| 2019-12-31 | ₩244.15 Billion | -2.45% |
| 2018-12-31 | ₩250.27 Billion | +3.48% |
| 2017-12-31 | ₩241.85 Billion | +6.27% |
| 2016-12-31 | ₩227.57 Billion | +3.10% |
| 2015-12-31 | ₩220.74 Billion | +5.46% |
| 2014-12-31 | ₩209.31 Billion | +2.63% |
| 2013-12-31 | ₩203.95 Billion | -- |